¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Transaminase clinical usage"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • clinical laboratory
    ÀÓ»ó°Ë»ç½Ç
  • clinical manifestation
    ÀÓ»óÁõ»ó, ÀÓ»ó¼Ò°ß
  • clinical material
    Àӻ󰡰˹°, ÀÓ»ó°Ëü
  • clinical medicine
    ÀÓ»óÀÇÇÐ
  • clinical otosclerosis
    ¹ßÇö±Í°æÈ­Áõ
  • clinical pathology
    ÀÓ»óº´¸®ÇÐ
  • clinical record
    ÀÓ»ó±â·Ï
  • clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®, ÀÓ»óÄ¡±Ù
  • clinical sign
    ÀÓ»ó¡ÈÄ
  • clinical significance
    ÀÓ»óÀûÁ߿伺
  • clinical skill
    ÀÓ»ó¼ú±â
  • clinical trial
    ÀÓ»ó½ÃÇè
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • good clinical practice
    ÀǾàǰÀÓ»ó½ÃÇè°ü¸®±âÁØ
  • objective structured clinical examination
    °´°ü±¸Á¶È­Áø·á½ÃÇè
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • clinical material
    Àӻ󰡰˹°, ÀÓ»ó°Ëü
  • clinical medicine
    ÀÓ»óÀÇÇÐ
  • clinical mycology
    ÀÓ»óÁø±ÕÇÐ
  • clinical otosclerosis
    ¹ßÇö±Í°æÈ­Áõ
  • clinical record
    ÀÓ»ó±â·Ï
  • clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®
  • clinical sign
    ÀÓ»ó¡ÈÄ
  • clinical significance
    ÀÓ»óÀûÁ߿伺
  • clinical skill
    ÀÓ»ó¼ú±â
  • clinical specimen
    ÀÓ»ó°Ë»ç¹°
  • clinical syndrome
    ÀÓ»óÁõÈıº
  • clinical trial
    ÀÓ»ó½ÃÇè
  • clinical ward
    ÀÓ»óº´µ¿
  • clinical dementia rating scale
    ÀÓ»óÄ¡¸ÅÆò°¡Ã´µµ
  • clinical target volume
    ÀÓ»óÇ¥ÀûüÀû
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • clinical crown
    ÀÓ»óÄ¡°ü(¡­öÍή).
  • clinical decision making
    ÀÓ»óÀû(ÀÎ) °áÁ¤
  • clinical dementia rating scale (CDRS)
    ÀÓ»óÀû Ä¡¸ÅÆò°¡(ìúßÉîÜ öÂØÜøÄʤ)ôµµ
  • clinical diabetes
    ÀÓ»ó(Àû) ´ç´¢º´ (¡­îÜÓØèñÜ»).
  • clinical diagnosis
    ÀÓ»ó(Àû) Áø´Ü(¡­òàÓ¨).
  • clinical effect
    ÀÓ»ó(Àû) È¿°ú
  • clinical efficacy
    ÀÓ»óÀûÀ¯È¿µµ, ÀÓ»óÀûÈ¿´É (À¯È¿¼º)
  • clinical finding
    ÀÓ»ó(Àû) ¼Ò°ß
  • clinical hematology
    ÀÓ»óÇ÷¾×ÇÐ(¡­úìäûùÊ).
  • clinical hematology
    ÀÓ»óÇ÷¾×ÇÐ(?Ì´Ëâ̰).
  • clinical immunology
    ÀÓ»ó¸é¿ªÇÐ
  • clinical implication
    ÀÓ¼ºÀû(ÀÎ) ¿µÇâ, °á°ú
  • clinical isolate
    ÀÓ»óºÐ¸®ÁÖ
  • clinical laboratory
    ÀÓ»ó°Ë»ç½Ç
  • clinical manifestation
    ÀÓ»óÁõ»ó(¡­ñøßÒ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AST ASpartate Transaminase(aminoTransferase)
  = SGOT
GOT Glutamic Oxaloacetic Transaminase
SGOT Serum Glutamic Oxaloacetic Transaminase
  = AST
SGPT Serum Glutamate(Glutamic) Pyruvate(Pyruvic Acid) Transaminase
  = ALT
EGOT erythrocytic glutamic oxaloacetic transaminase
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GOT Glutamate oxaloacetate transaminase
GPT Glutamate pyruvate transaminase
GOT Glutamic Oxaloacetic Transaminase
GPT Glutamic Pyruvic Transaminase
GPT Glutamic-pyruvate transaminase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • clinical resting position
    ÀÓ»óÀû ¾ÈÁ¤À§
  • clinical sign
    ÀÓ»ó ¡ÈÄ
  • clinical skill
    ÀÓ»ó ±â¼ú
  • clinical syndrome
    ÀÓ»ó ÁõÈıº, ÀÓ»óÀû ÁõÈıº
  • clinical unit
    ÀÓ»ó ´ÜÀ§
  • clinical-pathological correlation
    ÀÓ»ó-º´¸®ÇÐÀû »óÈ£°ü°è
  • controlled clinical study
    °ü¸®È­ ½ÃÇè, °ü¸®È­ ÀÓ»ó ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ÀÓ»ó ½ÃÇè
  • early clinical symptom
    Ãʱâ ÀÓ»ó Áõ»ó
  • lengthening of the clinical crown
    ÀÓ»ó Ä¡°ü ¿¬Àå¼ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
serum glutamic-pyruvic transaminase <enzyme> An enzyme that is found primarily in the liver. It is released into the bloodstream as the result of liver damage. Also called the alanine aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT).
(27 Sep 1997)
N6-acetyl-beta-lysine transaminase <enzyme> Involved in oxidative catabolism of lysine by candida maltosa; forms 2-keto-6-acetamidocaproate
Registry number: EC 2.6.1.65
Synonym: n6-acetyllysine transaminase, acl-at, n6-acetyllysine 2-oxoglutarate aminotransferase
(26 Jun 1999)
D-amino acid transaminase <enzyme> Catalyses the alpha,beta elimination of the (d)-isomer of beta-chloroalanine or other amino acids to yield pyruvate, chloride and ammonia
Registry number: EC 2.6.1.-
(26 Jun 1999)
ornithine-oxo-acid transaminase <enzyme> A pyridoxal phosphate enzyme that catalyses the formation of glutamate gamma-saemialdehyde and an l-amino acid from l-ornithine and a 2-keto-acid.
Chemical name: L-Ornithine:2-oxo-acid aminotransferase
Registry number: EC 2.6.1.13
(12 Dec 1998)
ornithine transaminase <enzyme> An enzyme that will reversibly catalyze the reaction of alpha-ketoglutarate and l-ornithine to form l-glutamate and l-glutamate gamma-saemialdehyde; a deficiency of this enzyme will result in gyrate atrophy of the choroid and retina.
Synonym: ornithine transaminase.
(05 Mar 2000)
transaminase <enzyme> A subclass of enzymes that catalyse the transfer of an amino group from a donor (generally an amino acid) to an acceptor (generally 2 keto acid) in a cyclic process using pyridoxal phosphate as cofactor, for example aspartate amino transferase catalyses the reaction: aspartate + ketoglutarate = oxaloacetate + glutamate.
(18 Nov 1997)
tyrosine-repressible transaminase <enzyme> From E coli; catalyses the amination of 2-ketoisocaproate to leucine; encoded by tyrb; a functional leuabcd operon is required for leucine synthesis by this enzyme
Registry number: EC 2.6.1.-
Synonym: transaminase d, tyrosine-2-ketoisocaproate aminotransferase
(26 Jun 1999)
tyrosine transaminase <enzyme> An enzyme that catalyses the conversion of l-tyrosine and 2-oxoglutarate to 4-hydroxyphenylpyruvate and l-glutamate. It is a pyridoxal-phosphate protein. L-phenylalanine can act instead of l-tyrosine. The mitochondrial enzyme may be identical with aspartate transaminase (ec 2.6.1.1.).
Chemical name: L-Tyrosine:2-oxoglutarate aminotransferase
Registry number: EC 2.6.1.5
(12 Dec 1998)
2,4-diaminobutyric acid transaminase <enzyme> Catalyses conversion of l-aspartate beta-saemialdehyde to l-2,4-diaminobutyric acid
Registry number: EC 2.6.1.46
Synonym: ectb gene product
(26 Jun 1999)
4-aminobutyrate transaminase <enzyme> An enzyme that converts brain gamma-aminobutyric acid (gaba) into succinate saemialdehyde, which can be converted to succinic acid and enter the citric acid cycle. It also acts on beta-alanine.
Chemical name: 4-Aminobutanoate:2-oxoglutarate aminotransferase
Registry number: EC 2.6.1.19
(12 Dec 1998)
Addison's clinical planes A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison.
(05 Mar 2000)
pathology, clinical A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids.
(12 Dec 1998)
chemistry, clinical The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy.
(12 Dec 1998)
pharmacology, clinical The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.
(12 Dec 1998)
phase I clinical trial <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose.
They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies.
The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs.
(31 Dec 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á